C-reactive protein test is used to test the level of C-reactive protein (CRP) concentration in the blood. C-reactive protein test is adopted to check for infections or any other medical conditions, and increases in cases of inflammation. C-reactive protein test is conducted in order to evaluate the chances of developing cardiovascular diseases such as coronary artery diseases, which further can lead to severe heart attack. It is believed that increased level of C-reactive protein is coupled with augmented risk of heart attacks, however, C-reactive protein test does not specify the direct cause of inflammation, but indicates inflammation level triggered by other causes. C-reactive protein test is used in patients who have low chances, approximately 5% to 10% of having a heart attack in upcoming years. C-reactive protein test also provides assistance in determining the risk of second heart attack, as high level of C-reactive protein in a patient with previous heart attack history have a high chance of having the further heart attack. In addition to that, C-reactive protein is produced by liver cells, and according to research conducted, they are used as an indicator for determining cardiovascular disease. C-reactive protein test is also adopted in patient suffering from autoimmune disorders such as rheumatoid arthritis and lupus, as this disease also cause inflammation.
The market for C-reactive protein test is primarily driven by increasing prevalence and incidence of cardiovascular disorders on a global level. As exemplified by the research conducted by American Heart Association (AHA) in 2017, cardiovascular disorders result in more than 801,000 deaths in the U.S. alone, and nearly 2,200 patients die of cardiovascular disease each day. In 2013, 31% of all global deaths are from cardiovascular diseases. In addition, growing elderly population coupled with increasing cases of diabetes mellitus are also driving the growth of C-reactive protein test market. However, scarcity of skilled professionals, low demand of C-reactive protein test compared to other blood tests, and adverse reaction concerns are the major obstacles to the growth of C-reactive protein test market.
The global C-reactive protein test market can be segmented on the basis of product type, analysis mode, application, end-user, and region.
C-reactive protein test is used as an indicator for detecting inflammation in cases of cardiovascular diseases, autoimmune disorders, infection, arthritis, cancer, or other cases. The high level of C-reactive protein greater than 2 mg/l is more prone to developing chronic artery diseases. C-reactive protein test is advantageous in applications where cholesterol test alone is insufficient. C-reactive protein is considered as safe, however, complications can lead to excessive bleeding, bruising or infection, and dizziness. Concentration of C-reactive protein greater than 10 mg/l may indicate osteomyelitis, autoimmune arthritis, tuberculosis, lupus, lymphoma, and pneumonia.
Geographically, global C-reactive protein test market can be segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. The market in North America is anticipated to show the largest market share for C-reactive protein test, followed by Europe, owing to the presence of sophisticated healthcare infrastructure. In addition, proper reimbursement policies, increasing prevalence and incidence of cardiovascular disorders are also impelling the growth of C-reactive protein test market.The market in Asia-Pacific region is estimated to grow at fastest CAGR over the forecast period owing to the presence of large population base coupled with growing geriatric population in countries such as Japan and China, and increasing trends towards point-of-care services. However, market in Latin America, and Middle East & Africa shows the steady growth during the forecast period.
Some of the market participants in the global C-reactive protein test market are Randox Laboratories Ltd., EKF, Getein Biotech, Inc., Goldsite Diagnostics Inc., Biomerica, Inc., SOBIODA, Gesan Production, Arlington Scientific, Inc., SD Biosensor, INC., and Teco Diagnostics.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
Regional analysis includes